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Key questions
What is already known?
 ► Current diagnostic tests for typhoid fever lack the 
sensitivity and specificity to be reliably used at the 
point- of- care (POC), resulting in the overuse of anti-
biotics through empiric treatment.
What are the new findings?
 ► To meet the needs of users in endemic regions, 
stakeholders proposed that an improved typhoid 
diagnostic test must be able to detect S. Paratyphi 
as well as S. Typhi, have a sensitivity ≥90%, a spec-
ificity ≥95% and have an end user cost of <US$3.
What do the new findings imply?
 ► To have a meaningful impact on the overuse of an-
tibiotics that has contributed to the emergence of 
antibiotic resistance in S. Typhi and other bacteria, 
an improved typhoid POC test needs to be used as 
part of a treatment algorithm in conjunction with 
diagnostics for malaria and other causes of acute 
febrile illness.
AbsTrACT
Introduction Typhoid fever is one of the most common 
bacterial causes of acute febrile illness in the developing 
world, with an estimated 10.9 million new cases and 116.8 
thousand deaths in 2017. Typhoid point- of- care (POC) 
diagnostic tests are widely used but have poor sensitivity 
and specificity, resulting in antibiotic overuse that has 
led to the emergence and spread of multidrug- resistant 
strains. With recent advances in typhoid surveillance and 
detection, this is the ideal time to produce a target product 
profile (TPP) that guides product development and ensure 
that a next- generation test meets the needs of users in the 
resource- limited settings where typhoid is endemic.
Methods A structured literature review was conducted 
to develop a draft TPP for a next- generation typhoid 
diagnostic test with minimal and optimal desired 
characteristics for 36 test parameters. The TPP was refined 
using feedback collected from a Delphi survey of key 
stakeholders in clinical medicine, microbiology, diagnostics 
and public and global health.
results A next- generation typhoid diagnostic test should 
improve patient management through the diagnosis and 
treatment of infection with acute Salmonella enterica 
serovars Typhi or Paratyphi with a sensitivity ≥90% and 
specificity ≥95%. The test would ideally be used at the 
lowest level of the healthcare system in settings without 
a reliable power or water supply and provide results in 
<15 min at a cost of <US$1.00.
Conclusion This report outlines the first comprehensive 
TPP for typhoid fever and is intended to guide the 
development of a next- generation typhoid diagnostic 
test. An accurate POC test will reduce the morbidity and 
mortality of typhoid fever through rapid diagnosis and 
treatment and will have the greatest impact in reducing 
antimicrobial resistance if it is combined with diagnostics 
for other causes of acute febrile illness in a treatment 
algorithm.
InTroduCTIon
Typhoid fever (typhoid) is an enteric bacte-
rial infection caused by Salmonella enterica 
serovar Typhi (Salmonella Typhi; S. Typhi). It 
is one of the most common bacterial causes 
of acute febrile illness in the developing 
world,1 with an estimated 10.9 million new 
cases worldwide and 116.8 thousand deaths 
in 2017.2 3 Paratyphoid fever caused by Salmo-
nella enterica serovars Paratyphi A, B and C (S. 
Paratyphi) results in a disease that can have 
an identical clinical syndrome to typhoid 
fever,4 but is often less severe.5 Typhoid 
fever is most common in South Asia and 
sub- Saharan Africa, with children predomi-
nantly affected. Like many febrile illnesses, 
typhoid presents with non- specific symptoms 
and signs, especially in its early stages. In 
routine healthcare settings in low/middle- 
income countries (LMICs), typhoid fever is 
commonly suspected and treated empirically 
with antibiotics.6 This overuse of antibiotics 
creates a selective pressure for the develop-
ment of antimicrobial resistance (AMR),7 that 
has resulted in the emergence and spread of 
typhoid strains that are resistant to all first- 
line antibiotics.8 Similarly, the low specificity 
of current rapid diagnostic tests (RDTs) can 
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lead to an over diagnosis of typhoid fever that may result 
in the overuse of antibiotics and delay the proper treat-
ment for underlying conditions. For example, the use of 
the Widal test during an outbreak of acute febrile illness 
in Nepal led to misdiagnosis of typhoid which delayed 
the appropriate treatment of the causative agent (scrub 
typhus), resulting in dozens of deaths.9 The potential 
harms of current typhoid RDTs are compounded by the 
fact they are widely available, cheap and easy to use.10
Various aspects of S. Typhi biology make diagnosis by 
standard laboratory methods challenging. S. Typhi is able 
to bypass the gastrointestinal mucosal barrier that restricts 
other enteric bacteria and can evade the typical innate 
immune responses with limited activation of inflamma-
tory pathways.11 S. Typhi infection begins with invasion 
of the mucosa of the terminal ileum, and the organism 
is thought to only be transiently present in the blood 
before dissemination throughout the reticuloendothe-
lial system into the bone marrow, liver and spleen.12 The 
bacterial load in peripheral blood peaks in the first week 
of illness,13 but is still very low with a median of 0.1–1.0 
colony- forming units/mL in symptomatic patients.14 This 
concentration is difficult to detect by blood culture or 
PCR, resulting in lower sensitivity for these diagnostic 
tests. S. Typhi is a member of the Enterobacteriaceae 
family, and antibodies that have been produced in 
response to prior infections with other Enterobacteria-
ceae tend to cross- react with S. Typhi,12 due to significant 
conservation of surface antigens. This cross- reactivity 
lowers the specificity of antibody- based diagnostic assays 
that otherwise are well suited for a simple, rapid and inex-
pensive test format. Compounding the challenge, the 
muted immune response that occurs through expression 
of the Vi capsular polysaccharide12 may further hinder 
the utility of serological tests for typhoid diagnosis.
In clinical settings supported by a microbiology labo-
ratory, invasive typhoid infection is confirmed through 
isolation of S. Typhi from blood cultures, but this is rela-
tively expensive, can take >48 hours, has low sensitivity 
and requires laboratory infrastructure and trained staff 
that are not commonly available in LMIC where typhoid 
is most prevalent.15 Bone marrow cultures have high 
sensitivity for detection of S. Typhi but are not routinely 
used because of the invasive techniques needed to 
obtain bone marrow aspirates. PCR testing for typhoid is 
expensive and has a low diagnostic sensitivity when used 
on peripheral blood samples.16 Other available point- 
of- care (POC) diagnostic tests include the Widal test,17 
TUBEX,18 Typhidot,19 Test- it Typhoid20 and the Typhoid- 
Paratyphoid diagnostic assay (TPTest). However, these 
tests all have significant drawbacks that limit their clinical 
use.
Serological tests are limited by low antibody titers 
in the early stage of infection and may produce false- 
negative results for IgM- based assays depending on the 
timing of testing.21 The Widal test is a quantitative agglu-
tination test that identifies serum antibodies against 
Salmonella antigens O- somatic and H- flagellar. The test is 
considered positive if a convalescent phase serum sample 
has a fourfold higher titer than an acute sample. But the 
Widal test is often applied incorrectly with just a single 
acute phase sample used for diagnosis and treatment.22 
A Cochrane review of the accuracy of the commercially 
available antibody- based rapid RDTs showed moderate 
sensitivity and specificity for the TUBEX colorimetric 
test that detects anti- O:9 antibody titres (78%, 87%), the 
Typhidot dot ELISA that measures IgG and IgM anti-
bodies against the outer membrane proteins of S. Typhi 
(84%, 79%) and the Test- it Typhoid immunochromato-
graphic lateral flow assay that detects IgM antibodies 
against S. Typhi O antigen (69%, 90%).23 The TPTest is 
a newer serological test that detects circulating IgA using 
ELISA with a sensitivity and specificity of >95%.24 But this 
assay is not commercially available, takes 24–48 hours to 
produce a result, and requires isolation and culturing of 
peripheral blood mononuclear cells which is technically 
challenging, utilising equipment not widely available in 
resource- limited settings.14 24 Due to the limited sensi-
tivity of all current typhoid POC tests they cannot be 
relied on to guide treatment prescribing.
If developed and implemented effectively, an accu-
rate typhoid RDT could reduce morbidity and mortality 
through faster diagnosis. Further, it could help to reduce 
the overuse of antibiotics that contributes to the emer-
gence and spread of multidrug- resistant strains of S. Typhi 
and other bacteria. In recent years, novel approaches have 
been described to develop typhoid diagnostic tests with 
improved accuracy in resource- limited settings, including 
serological, molecular, metabolomic, proteomic and tran-
scriptomic methods.7 For example, a recent study has 
shown that IgA and IgM against S. Typhi lipopolysaccha-
ride may be a specific marker of acute typhoid infection 
and is a promising target for diagnostic test development.25
As the need for appropriate fever case management 
becomes more apparent,26 the need for improved typhoid 
diagnostics suitable for use in low- resource environments 
becomes more pressing. Building on the recent momentum 
around improved typhoid surveillance27 and advances in 
typhoid detection,1 this report describes the development 
of a target product profile (TPP) in an attempt to define 
the diagnostic needs for this important pathogen. The TPP 
is intended to guide product development and to ensure 
an optimised solution that meets the needs of endemic 
countries and results in tangible improvements in patient 
management. In addition, the TPP aims to reinvigorate 
the discussion of diagnostics as a crucial part of the global 
typhoid agenda. This report focuses on the process of TPP 
development with an emphasis on key test characteristics 
and discussion points identified by typhoid experts and 
experienced stakeholders.
MeTHods
data gathering
A structured review of relevant literature related to Salmo-
nella Typhi diagnosis was performed to develop a draft 
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Table 1 Typhoid target product profile parameters
Category Test characteristic
Scope of test Goal
Target population
Target user
Target level of health system
Test performance Sample type
Sample collection
Sample volume/ sample transfer device
Additional sample preparation
Ease of use
Hands on time
Time to result
Read out of results
In use stability
Data output +connectivity
Data interpretation
Analyte type
Multiplexing
Analytical sensitivity/limit of detection
Diagnostic sensitivity
Diagnostic specificity
Reproducibility
Operational 
characteristics
Kit configuration
Reagent preparation
Operating conditions
Transportation and storage stability
Equipment (instrumentation external to 
test)
External maintenance
Calibration
Internal/ process control
Batch/quality control
Power requirements
Water requirement
Waste disposal
Bio- safety
Training requirements
Cost per test
TPP with minimal and optimal desired characteristics for 
a next- generation typhoid diagnostic test. The test char-
acteristics chosen for the TPP were selected based on 
previous TPPs published by the Foundation for Innova-
tive New Diagnostics (FIND),28 29 and include the scope, 
target population, intended use, expected test perfor-
mance, as well as operational and financial parameters 
(table 1). Each desired test characteristic was classified 
as either a minimum requirement that a test must meet 
to be useful for healthcare providers treating patients in 
resource- limited settings, or an optimum threshold that 
would make the test highly desirable for both health-
care providers and patients. The Ovid Medline database 
was accessed on 21 June 2018 using the Medical Subject 
Heading (MeSH) ‘Typhoid fever’ and the subheading 
‘Diagnosis’. Results were restricted to English language 
articles published in the previous 10 years. Titles and 
abstracts of retrieved articles were scanned for relevance, 
with articles of interest thoroughly reviewed by RGM for 
content relevant to the TPP. Additional documents were 
identified by searching for ‘typhoid’ on the websites of 
the Cochrane library, WHO and FIND, and by screening 
references and studies that cited articles selected in the 
initial search. Expert stakeholders to be contacted for 
the Delphi survey were identified as part of the literature 
review.
delphi survey
Stakeholders were contacted for input on the draft TPP 
using a Delphi survey. Stakeholders included special-
ists in clinical medicine (n=14), laboratory medicine 
(n=2), microbiology (n=6), diagnostics (n=11) and 
public health and global health (n=6). An online survey 
(online supplementary file 1) was used and respondents 
were asked to rate their agreement with each of the TPP 
characteristics using a Likert scale (1=strongly disagree, 
2=disagree, 3=neither agree nor disagree, 4=mostly agree, 
5=fully agree). A consensus agreement was defined as 
≥75% of respondents who either mostly or fully agreed 
with a TPP characteristic. Results from the first round of 
the survey (October 2018) were used to refine the TPP, 
and a second draft of the TPP was distributed (November 
2018) to all initial participants as well as two additional 
stakeholders identified after the first round of the survey 
was completed.
Patient and public involvement
While key stakeholders were involved in developing the 
TPP, there was no patient or public involvement in this 
research.
resulTs
An Ovid Medline search using the MeSH Typhoid 
fever produced 10 698 results, with 1558 results for the 
subheading Diagnosis. Limiting search results to English 
language articles published after 1 January 2008, provided 
298 articles that were screened for relevance. Additional 
documents were included as outlined in the Methods 
section and selected articles were thoroughly reviewed to 
develop a draft typhoid TPP with minimum and optimum 
criteria for the test characteristics in table 1.
Feedback on the draft TPP was obtained from key stake-
holders through the first round of the Delphi survey, with 
40 stakeholders contacted and 19 (19/40, 48%) completed 
surveys received. Survey respondents reported having expe-
rience working in low- resource settings in Africa (n=14), 
the Americas (n=2), Europe (n=2), the Eastern Mediterra-
nean (n=2), South- East Asia (n=12) and the Western Pacific 
region (n=2), with multiple respondents reporting experi-
ence in more than one region. Consensus agreement of 
≥75% was achieved for 34/36 (94%) TPP criteria. TPP 
criteria that generated the most discussion in the Delphi 
survey were related to the scope of the test including the 
goal, target population, level of the healthcare system, 
diagnostic sensitivity and specificity, as well as cost. Based 
on feedback from survey respondents, ‘multiplexing’ 
was removed as a TPP characteristic, and the remaining 
minimum and optimum TPP criteria were revised. For 
criteria that had achieved consensus agreement, revisions 
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Table 2 Typhoid target product profile characteristics: scope of the test
Characteristic Minimal requirement Optimal requirement References
Goal Point- of- care test to improve patient 
management through diagnosis and 
treatment of infection with acute 
Salmonella enterica serovars Typhi or 
Paratyphi
Combine with diagnostics for 
malaria and other causes of acute 
febrile illness as part of a treatment 
algorithm
8 41
Target population All individuals with undifferentiated acute fever 15 27 30
Target user Laboratory technician Healthcare worker 7
Target level of health system* District hospital with basic laboratory 
facilities
Primary health posts and centres 6 31
*Consensus not reached among survey respondents.
Table 3 Test performance characteristics for a typhoid diagnostic target product profile
Characteristic Minimum requirement Optimum requirement References
Sample type Venous blood Capillary blood or less invasive sample 
type (eg, saliva), excluding stool and 
urine
12 28
Sample collection Transfer and quantification device included in the test Industry standard
Sample volume/ 
sample transfer device
≤1 mL venous blood ≤100 µL capillary blood 47
Additional sample 
preparation
2 sample processing steps None required May need to separate 
serum from whole blood 
before applying to RDT
Ease of use ≤5 steps, of which≤2 are timed ≤3 steps, of which≤1 is timed 6
Total hands- on time ≤5 min ≤1 min 7 28
Time to result ≤2 hours ≤15 min 28 34
Read out of results Binary results 6
In use stability Results stable ≥15 min Results stable ≥1 hour 28
Data output and 
connectivity
No wireless connectivity required Wireless connectivity used to transfer 
data
48
Data interpretation Readout easily interpretable by 
non- laboratory personnel
No data interpretation required 7
Analyte type Any acceptable analyte, or combination of analytes, that can meet 
sensitivity and specificity thresholds
7
Analytical sensitivity/ 
limit of detection
Limit of detection should be such that it allows clinically relevant 
performance as defined below
7
Diagnostic sensitivity* ≥90% ≥95% 22 23 35–37
Diagnostic specificity ≥95% ≥98% 22 23 35–37
Reproducibility Kappa ≥0.9 between different operators and laboratories/locations 49
*Consensus not reached among survey respondents.
were made if survey respondents provided compelling 
suggestions for improvement.
A second draft of the TPP was distributed to the 19 
people who responded to the initial Delphi survey, and 
two additional stakeholders identified after comple-
tion of the first round. A total of 12 completed surveys 
were received from 13 stakeholders, including two who 
submitted a joint survey, with consensus agreement 
achieved for 33/35 (94%) TPP characteristics. The two 
criteria that did not meet the consensus threshold were 
the target level of the health system and diagnostic sensi-
tivity, both of which received 67% agreement. Survey 
respondent feedback was used to revise these two criteria, 
and to make minor changes to four criteria that had ≥75% 
agreement, before inclusion in the final version of the 
TPP presented in tables 2–4.
scope of test
Delphi survey feedback emphasised that a next- 
generation RDT for typhoid fever should not focus solely 
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Table 4 Consensus operational characteristics for the typhoid target product profile
Characteristic Minimum requirement Optimum requirement References
Kit configuration Package of single kits sharing reagents (if 
required) and user manual. Instructions in 
English, French, Spanish and Portuguese
Package of single kits with 
individual reagents (if required) 
sharing user manual. Instructions in 
local languages
28 38
Reagent preparation One reagent preparation step None required 28 39
Operating conditions  ► Between 5°C and 40°C
 ► ≤90% relative humidity
 ► Between 5°C and 45°C
 ► ≤90% relative humidity
38
Transportation and 
storage stability
≥12 months at ≤35 °C and ≤70% relative 
humidity, no cold chain needed, ability 
to withstand transport stress (≤3 days at 
60 °C)
≥24 months at ≤45 °C and ≤90% 
relative humidity, no cold chain 
needed, ability to withstand 
transport stress (≤3 days at 60 °C)
38
Equipment 
(instrumentation external 
to test)
Small, portable or handheld, battery- 
operated instrument
No equipment 6 7
External maintenance Minimal maintenance, simple to perform 
by non- laboratory personnel
No maintenance 28
Calibration ≤1 annual calibration, ideally 
autocalibration by operator or remotely
No calibration 28
Internal/ process control Included in each assay Industry standard
Batch/quality control Positive and negative controls included in each kit Industry standard
Power requirements Battery or solar powered No power needed 28
Water requirement No external water required 28
Waste disposal Biohazard waste, sharps disposal No toxic waste requiring special 
disposal
50
Bio- safety Basic biosafety level 1, WHO Class B In- 
vitro diagnostic (moderate individual and 
low public health risk)
Basic biosafety level 1, WHO Class 
A In- vitro diagnostic (low individual 
and low public health risk).
50 51
Training requirements ≤0.5 days for lab technician ≤0.5 days for experienced health 
worker
6 7 23
Cost per test End- user cost <US$3.00 End- user cost <US$1.00 7 28
on the diagnosis of S. Typhi. To reduce the empiric use 
of antibiotics that generates selective pressure for AMR, 
a typhoid RDT would ideally be combined with diagnos-
tics for malaria and other causes of acute febrile illness as 
part of a case management algorithm (table 2). Due to 
the similar clinical presentation and the changing epide-
miology of S. Typhi and S. Paratyphi, survey respond-
ents advised that a next- generation test for typhoid fever 
should be able to detect both S. Typhi and S. Paratyphi.
The target population was identified based on published 
data from Africa and Asia.27 30 Children aged 2–14 years 
bear the brunt of the global typhoid burden but there is 
substantial variability both within and between regions in 
terms of who is most affected. A recent study from Paki-
stan found higher rates of typhoid fever in adults than in 
children.30 These data highlight the need for a typhoid 
RDT that can detect the disease in individuals of all ages, 
as confirmed by the Delphi survey. A next- generation 
typhoid POC test should be able to accurately diagnose 
typhoid in all individuals with undifferentiated acute 
fever at any point in their disease course from the onset 
of fever until the time they present for care.
When designing new diagnostic tests, the level of the 
healthcare system where a test will be deployed is an 
important consideration. Ghani et al have identified five 
healthcare system levels, with different types of diagnostic 
or prognostic tools suitable for different levels.31 Typhoid 
is most prevalent in LMIC with limited healthcare 
resources, and in these contexts the optimal typhoid test 
would not require sophisticated equipment and could 
be easily interpreted by non- laboratory personnel.6 7 
Respondents agreed that a test would optimally be usable 
at the lowest level of a healthcare system, which in many 
cases is a community health worker seeing patients in an 
informal environment. However, as the current gold stan-
dard of blood culture requires laboratory equipment, but 
has suboptimal sensitivity and specificity, some respon-
dents felt it was acceptable for a typhoid RDT to require 
basic laboratory facilities, with a trained laboratory tech-
nician, providing it meets all other TPP criteria. Based on 
feedback from the initial round of the Delphi survey the 
minimum target level was adjusted upward to a higher 
level of the healthcare system, but consensus agreement 
was not achieved as some respondents felt strongly that 
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the minimum requirement should be a test that can be 
used in informal settings at the lowest level of the health-
care system.
Test performance
Blood culture is commonly used as the reference 
standard for typhoid diagnosis but requires sophisticated 
equipment not readily available in LMIC where typhoid 
is endemic.6 Typhoid blood cultures require a minimum 
of 2–10 mL of venous blood due to the low bacterial load 
in peripheral blood, and have poor sensitivity estimated 
at only 61% in a recent systematic review.32 A composite 
reference standard (CRS) that combines multiple tests 
with high specificity but suboptimal sensitivity has been 
proposed as a possible way to improve diagnostic accu-
racy.7 33 Various test combinations have been used as a 
CRS for typhoid,33 but respondents in this Delphi exercise 
advised that the adoption of a standardised composite is 
required before it can be included in a TPP.
The most commonly used typhoid POC tests (Widal, 
Typhidot, Tubex, Test- It Typhoid, TPTest) require 
between 5 µL and 1 mL of blood, but have only moderate 
sensitivity and specificity.23 Survey respondents agreed 
that an optimal next- generation typhoid RDT would 
use a capillary blood sample with a volume of ≤100 µL, 
or a less invasive sample type, excluding urine and 
stool.12 28 However, survey respondents indicated that 
≤1 mL of venous blood was an acceptable minimum 
requirement due to the current difficulty in accurately 
diagnosing typhoid fever (table 3). The TPP allows for 
up to two sample processing steps as an RDT may require 
serum to be separated from whole blood, with at most 
five steps for the test of which no more than two should 
be timed,28 and a total hands on time of <5 min. Based 
on a published expert consensus TPP for diagnostics for 
acute febrile illness, RDT performance ideally would 
entail three or fewer steps, of which at most one step is 
timed, with a total hands- on time of 1 min or less.28
For a new typhoid diagnostic test to have the greatest 
impact on prescribing and clinical outcomes it would 
need to yield results in less than a few hours.34 There 
was consensus agreement that the optimum require-
ment would make results available within 15 min to coin-
cide with the average development time of other POC 
diagnostics commonly used in LMIC environments (for 
example, malaria antigen- detecting RDTs). A minimum 
requirement of results within 2 hours was agreed; this 
would be a significant improvement from the ≥48 hours 
required for blood culture, and 2 hours was deemed the 
longest time that outpatients could wait for test results, 
particularly in rural settings where patients may have to 
travel long distances to reach a health facility.28
Researchers have proposed that an ideal typhoid diag-
nostic test would have a simple positive/negative read- out 
similar to a home pregnancy test,6 with results easily 
interpretable by non- laboratory personnel.7 The typhoid 
TPP therefore requires a binary read- out of results, with 
data that either do not require interpretation, or that are 
easily interpretable. No specific analyte or limit of detec-
tion is specified for the typhoid TPP, with any analyte or 
combination of analytes acceptable providing the test 
meets all other TPP requirements.
The minimum TPP requirement for diagnostic sensi-
tivity is ≥90%, with an optimum sensitivity of ≥95%, based 
on modelling data and expert opinion.22 23 35–37 Consensus 
agreement in the Delphi survey was not achieved for 
test sensitivity, which reflects the substantial variation in 
published expert opinions regarding the desirable accu-
racy for a typhoid RDT. However, survey respondents did 
agree on a minimum specificity of 95% and an optimum 
specificity of 98%.
operational characteristics
Survey respondents agreed on operational characteristics 
of the typhoid TPP (table 4). Typhoid diagnostic test kits 
ideally should consist of individually packaged tests with 
individual reagents (if required) and a user manual in 
local languages, based on TPP characteristics for other 
POC tests in regions where typhoid is endemic.28 38 39 Up 
to one reagent preparation step is acceptable, to allow 
for reconstitution of a powdered reagent. The test should 
not require a cold chain, with operating conditions that 
reflect the high temperatures and humidity that are 
present in many regions in Africa and Asia where typhoid 
is prevalent.
Currently, most typhoid treatments are provided in 
outpatient settings, including informal medical shops, 
so an ideal POC test would not require any sophisti-
cated equipment or a formal laboratory infrastructure.7 
A small, portable or handheld battery- operated instru-
ment is acceptable,40 but ideally no equipment would be 
required. To be truly transformative, a typhoid POC test 
needs to be useable in settings without a reliable power 
or water supply. If power is required, then it should be 
provided by a combination of rechargeable batteries and 
solar power.
Empiric treatment of suspected typhoid cases is 
common, typically using relatively inexpensive antibi-
otics.7 To reduce the overuse of empiric antibiotics, the 
end- user cost for a typhoid POC test was set at <US$3.00 
(minimum requirement) or <US$1.00 (optimum 
requirement) to reflect the cost of empiric antibiotics in 
endemic regions.7 Delphi survey feedback indicated that 
the highest cost to the end- user in Africa should be equiv-
alent to US$1.
dIsCussIon
Typhoid diagnostic tests currently lack the sensitivity and 
specificity required for an accurate diagnosis at the POC, 
resulting in the overuse of antibiotics through empiric 
treatment. The WHO has developed a list of character-
istics that make a test suitable for the resource- limited 
settings where typhoid is prevalent: the ASSURED 
acronym stands for affordable, sensitive, specific, user- 
friendly, rapid and robust, equipment- free, and delivered 
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to those in need.40 TPPs build on these criteria and 
increasingly are used in the global health community 
to guide development of diagnostic tests and to inform 
donors about global health priorities.28 38 39 This TPP 
outlines the minimum and optimum desired character-
istics for an improved typhoid RDT and is intended to 
accelerate development of optimised diagnostics that 
meet the needs of users in endemic regions.
Antibiotic resistance is a growing threat to typhoid 
treatment, with strains of S. Typhi that are resistant to 
three first- line agents now prevalent in parts of Asia and 
Africa.8 The emergence of a multidrug- resistant clone in 
Sindh, Pakistan that has acquired additional resistance to 
fluoroquinolones and third- generation cephalosporins, 
known as extensively drug- resistant S. Typhi, has left azith-
romycin and the costly intravenous carbapenem drugs 
as the only antibiotic options for some patients.8 There 
have been sporadic case reports of azithromycin- resistant 
S. Typhi,8 but if extremely drug- resistant strains acquire 
azithromycin resistance, carbapenems could be left as the 
only effective treatment. To prevent the further spread 
of resistant S. Typhi it would be beneficial to conduct 
drug susceptibility testing for individual patients before 
commencing antibiotic therapy. Drug susceptibility 
testing was not included as a TPP requirement because it 
is not likely to be feasible in non- culture POC tests due to 
the evolving nature of typhoid resistance8 and may make 
interpretation of test results too complex for users at the 
lowest healthcare level.31 However, some Delphi survey 
respondents felt that for an RDT ever to replace blood 
culture it must include susceptibility testing. An RDT for 
diagnosis combined with epidemiological knowledge of 
the antibiotic sensitivity of strains, updated at intervals, 
could be a compromise solution.
The 2017 Global Burden of Disease study estimated 
that S. Paratyphi affected 3.4 million people annually, 
with 19.1 thousand deaths, compared with 10.9 million 
cases and 116.8 thousand deaths for S. Typhi.2 3 The 
higher morbidity and mortality of S. Typhi makes it a 
greater public health concern, but the increasing preva-
lence of S. Paratyphi in certain regions makes it prudent 
for a next- generation test to detect S. Paratyphi as well 
as S. Typhi.5 41 42 Delphi survey feedback noted that not 
being able to detect S. Paratyphi could undermine clini-
cian confidence in a next- generation typhoid POC test 
as S. Typhi and S. Paratyphi may cause indistinguishable 
clinical syndromes.4 As drug- resistant typhoid continues 
to spread, it may become necessary to differentiate 
between these two serovars prior to starting therapy due 
to different antibiotic susceptibility profiles.43
The minimum diagnostic requirement for a typhoid 
RDT in this TPP was ≥90% sensitivity and ≥95% speci-
ficity, with an optimum threshold of ≥95% sensitivity and 
≥98% specificity. Consensus agreement was achieved 
in the Delphi survey for specificity but not sensitivity, 
reflecting the substantial variability seen in the published 
literature with proposed targets ranging from 80%–90% 
for sensitivity and 90%–98% for specificity.23 36 37 The 
poor sensitivity of blood culture as a reference standard 
for typhoid diagnosis makes it difficult to accurately 
assess the performance of novel diagnostic tests.33 Diag-
nostic accuracy can be improved by reliably identifying 
alternative infections and by using a CRS that incorpo-
rates the results of multiple tests.7 CRSs that have been 
used for typhoid diagnosis include culture and/or clin-
ical findings; culture and/or Widal test; culture and/
or PCR; culture, Widal test and/or clinical finding; and 
culture, PCR and/or Widal test.33 Evaluation of CRSs has 
been limited by a lack of consistency between studies, 
with a systematic review identifying 21 studies that stated 
use of a CRS as the reference method for a typhoid diag-
nostic test, but no 2 studies utilised an identical CRS. For 
a CRS to be reproducible, it has been proposed that the 
individual test components need to be standardised, with 
clinical signs that match the WHO definition of suspected 
typhoid fever, assays that are commercially available and 
well- defined blood culture parameters.33 Further work is 
needed to identify a standardised CRS before it can be 
included in a typhoid TPP.
Typhoid fever is transmitted by the faeco- oral route 
in water and food contaminated by S. Typhi in human 
faeces and so is endemic in low- resource environments 
that lack access to clean water and adequate sanitation. 
While improvements in the infrastructure for water, sani-
tation and hygiene could reduce or eliminate typhoid, 
these are costly long- term endeavours. The newly 
approved Typbar- TCV vaccine may help to reduce the 
global burden of enteric fever caused by S. Typhi,44 but 
an improved diagnostic test is required to accurately esti-
mate disease incidence and facilitate targeted vaccine 
deployment. To have a meaningful impact on the overuse 
of antibiotics that has contributed to the emergence of 
resistance in S. Typhi and other bacteria, an improved 
typhoid POC test needs to be used as part of a treatment 
algorithm in conjunction with diagnostics for malaria 
and other causes of acute febrile illness. The isolated use 
of a disease- specific diagnostic test for a febrile patient 
may help focus treatment if positive, but a negative test 
may result in alternative empiric antibiotic therapy, as 
seen for malaria.26 45 Drug susceptibility testing for S. 
Typhi, performed at reference laboratories, could inform 
local treatment algorithms based on regional antibiotic 
susceptibilities.46
This work provides the first comprehensive TPP for a 
next- generation POC test for typhoid fever. The main 
limitations of this study were the lack of consensus 
agreement for all TPP characteristics, and the relatively 
low- response rate in the second round of the Delphi 
survey. The length of the survey may have been a barrier 
to completion due to the amount of time required to 
provide feedback on all 35 TPP characteristics. Further 
discussion among the typhoid community is needed to 
settle on the optimal target level of the healthcare system 
and the required diagnostic sensitivity. While this TPP is 
a first- step towards improved awareness of the typhoid 
diagnostic needs, it is crucial to keep the conversation 
 o
n
 N
ovem
ber 9, 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2019-001831 on 31 October 2019. Downloaded from 
8 Mather RG, et al. BMJ Global Health 2019;4:e001831. doi:10.1136/bmjgh-2019-001831
BMJ Global Health
going and to engage global health funders, diagnostics 
developers and national policymakers in the discussion 
on how improved diagnostic tools and related innova-
tions can be used to improve surveillance data as well as 
support patient management decisions in the context of 
universal healthcare.
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